Kennett Sprogøe

This inventor holds 30 USPTO granted patents and 36 published patent applications, primarily in Controlled-Release Therapies. Top assignees: Ascendis Pharma Bone Diseases A/s, Ascendis Pharma Growth Disorders A/s, Ascendis Pharma A/s. Active years: 2014-2026.

USPTO Granted Patents = 30 (Patent Applications = 36)

% Patents Active = 93.3

Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 78(Granted Patents)

Location History:

Palo Alto, CA (US) (2014 - 2021)
Holte, DK (2017 - 2024)

Company Filing History:

10 out of 10

Ascendis Pharma Bone Diseases A/s

patents

10 out of 14

Ascendis Pharma Growth Disorders A/s

Ascendis Pharma Endocrinology Division A/s

patents

5. 1 out of 1

Ascendis Pharma Ophthalmology Division A/s

patent

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Controlled-Release

CNP Agonists

PTH Compounds

PEGylated Hormones

Growth Hormone

Prodrugs

Sustained Release

Combination Therapy

Pharmaceutical Formulations

Dosage Regimen

Ocular Treatments

Treprostinil

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12667604 - Combination Therapy with Controlled-Release CNP Agonists (2026-06-30),

2. 12544428 - CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS (2026-02-10),

3. 12453778 - Incremental dose finding in controlled-release PTH compounds (2025-10-28),

4. 12403182 - Liquid pharmaceutical formulations of PTH conjugates (2025-09-02),

5. 12303553 - Long-acting growth hormone dosage forms with superior efficacy to daily somatropin (2025-05-20),

6. 12295989 - Controlled-release PTH compound (2025-05-13),

7. 12274737 - PEGylated recombinant human growth hormone compounds (2025-04-14),

8. 12239689 - Controlled-release CNP agonists with low initial NPR-B activity (2025-03-04),

9. 12214020 - PTH prodrugs (2025-02-04),

10. 12156917 - CNP prodrugs with carrier attachment at the ring moiety (2024-12-03),

11. 12083182 - Controlled-release CNP agonists with increased NEP stability (2024-09-10),

12. 12016903 - Long-acting growth hormone treatment (2024-06-25),

13. 11918628 - Controlled-release PTH compound (2024-03-05),

14. 11890326 - Controlled-release PTH compound (2024-02-06),

15. 11857603 - PTH compounds with low peak-to-trough ratios (2024-01-02),

Title: Kennett Sprogøe - The Innovative Mind from Holte

Introduction: Kennett Sprogøe, a distinguished inventor hailing from Holte, Denmark, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Kennett Sprogøe's latest patents focus on advancements in renewable energy technologies, particularly in the development of solar-powered devices for sustainable living.

Career Highlights: Throughout his illustrious career, Kennett Sprogøe has been instrumental in creating cutting-edge solutions for environmental challenges, earning him recognition as a pioneer in the green technology sector.

Collaborations: Kennett Sprogøe has collaborated with leading research institutions and universities worldwide to further his innovative projects, showcasing his commitment to fostering collaboration and knowledge-sharing in the industry.

Conclusion: Kennett Sprogøe's passion for innovation and dedication to creating a more sustainable future through his inventive work continue to inspire and shape the landscape of technological advancements globally.